Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy

American Journal of the Medical Sciences

Volumn 327, Issue 6, 2004, Pages 315-318

  Rao, Archana ^a   D'Amico, Susana ^a   Balasubramanyam, Ashok ^a   Maldonado, Mario ^a,b  

^a BEN TAUB GENERAL HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Fenofibrate; Fibrates; HIV lipodystrophy; Hyperlipidemia; Hypertriglyceridemia

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRY; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIET RESTRICTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

EID: 2942655667     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200406000-00003     Document Type: Article

References (21)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-33.
2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
3. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9.
4. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. HIV Medicine Unit and Centre for Immunology, St Vincent's Hospital, Sydney, Australia. AIDS 1998;12:F51-8.
5. Panse I, Vasseur E, Raffin-Sanson ML, et al. Lipodystrophy associated with protease inhibitors. Br J Dermatol 2000; 142:496-500.
6. Ho TT, Chan KC, Wong KH, et al. Abnormal fat distribution and use of protease inhibitors. Lancet 1998;351:1736-7.
7. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998;12:F37-9.
8. Williamson K, Reboli AC, Manders SM. Protease inhibitor-induced lipodystrophy. J Am Acad Dermatol 1999;40:635.
9. Hadigan C, Meigs JB, Grinspoon S, et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 2003;36:909-16.
10. Sekhar RV, Jahoor F, White AC, et al. Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab 2002;283:E332-7.
11. Murray M, Lumpkin MD. FDA Public Health Advisory. Reports of Diabetes and Hyperglycemia in Patients Receiving Protease Inhibitors for the Treatment of Human Immunodeficiency Virus (HIV). Bethesda, MD: Food and Drug Administration; 1997.
12. Henry K, Melroe H, Huebesch J, et al. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998;352:1031-2.
13. Moyle GJ, Lloyd M, Reynolds B, et al. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 2001;15:1503-8.
14. Hadigan C, Rabe J, Grinspoon S, et al. Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution. Am J Clin Nutr 2003;77:490-4.
15. Balasubramanyam A, Sekhar RV, Jahoor F, et al. Pathogenesis of the HAART-associated metabolic syndrome: a model of "systemic steatosis." Curr Opin Lipidol 2004;15:59-67.
16. National Cholesterol Education Program. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:248-297.
17. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002;31:257-75.
18. Dube MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000;31:1216-24.
19. Miller J, Brown D, Amin J, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 2002;16:2195-200.
20. Schliefer K, Wasmuth JC, Braitinger D, et al. Efficacy of bezafibrate in the treatment of PI-induced hyperlipidemia-36 week data [abstract WePeB4214]. 13th International AIDS Conference. Durban, South Africa, July 9-14, 2000.
21. Nystrom T, Bratt G, Sjoholm A. Bezafibrate-induced improvement in glucose uptake and endothelial function in protease inhibitor-associated insulin resistance. J Intern Med 2002;252:570-4.